Newer therapeutic strategies for soft-tissue sarcomas

Metastatic soft-tissue sarcoma (STS), a devastating disease, has a median overall survival of only 12–18 months. Until recently, therapeutic options were limited and relied primarily on the use of anthracycline-based chemotherapy. Over the past two decades, improvement in the knowledge of the biology of STS has allowed the investigation of new therapeutic strategies including new cytotoxic agents, epigenetic drugs, specific targeted therapies, and immunotherapeutic treatments.